Oct 31 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX :
* NEUREN PHARMACEUTICALS LTD ANNOUNCES COMMENCEMENT OF PHASE 3 TRIAL OF TROFINETIDE IN RETT SYNDROME IN UNITED STATES
* US FDA HAS GRANTED ORPHAN DRUG DESIGNATION AND FAST TRACK DESIGNATION FOR RETT SYNDROME PROGRAM